Clinical Trial Detail

NCT ID NCT02386111
Title A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

clear cell renal cell carcinoma

Therapies

Sunitinib + Varlilumab

Age Groups: adult

No variant requirements are available.